- Home
- SVMH vs QLGN Comparison
SVMH vs QLGN Comparison
Compare SVMH & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVMH
- QLGN
- Stock Information
- Founded
- SVMH 2018
- QLGN 1996
- Country
- SVMH Cayman Islands
- QLGN United States
- Employees
- SVMH N/A
- QLGN 4
- Industry
- SVMH
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- SVMH
- QLGN Health Care
- Exchange
- SVMH Nasdaq
- QLGN Nasdaq
- Market Cap
- SVMH 3.1M
- QLGN 2.7M
- IPO Year
- SVMH N/A
- QLGN N/A
- Fundamental
- Price
- SVMH $0.02
- QLGN $3.60
- Analyst Decision
- SVMH
- QLGN
- Analyst Count
- SVMH 0
- QLGN 0
- Target Price
- SVMH N/A
- QLGN N/A
- AVG Volume (30 Days)
- SVMH 46.5M
- QLGN 226.0K
- Earning Date
- SVMH 11-22-2024
- QLGN 11-29-2024
- Dividend Yield
- SVMH N/A
- QLGN N/A
- EPS Growth
- SVMH N/A
- QLGN N/A
- EPS
- SVMH N/A
- QLGN N/A
- Revenue
- SVMH $42,538.00
- QLGN N/A
- Revenue This Year
- SVMH N/A
- QLGN N/A
- Revenue Next Year
- SVMH N/A
- QLGN N/A
- P/E Ratio
- SVMH N/A
- QLGN N/A
- Revenue Growth
- SVMH N/A
- QLGN N/A
- 52 Week Low
- SVMH $0.02
- QLGN $3.55
- 52 Week High
- SVMH $1.26
- QLGN $39.15
- Technical
- Relative Strength Index (RSI)
- SVMH 25.37
- QLGN 25.42
- Support Level
- SVMH $0.02
- QLGN $3.71
- Resistance Level
- SVMH $0.04
- QLGN $4.56
- Average True Range (ATR)
- SVMH 0.01
- QLGN 0.65
- MACD
- SVMH 0.00
- QLGN -0.06
- Stochastic Oscillator
- SVMH 9.30
- QLGN 2.08
About SVMH SRIVARU Holding Limited
SRIVARU Holding Ltd focuses to revolutionize two-wheeled vehicles (TWV) by developing products powered by renewable energy, which are assured for safety, performance, and comfort, thereby providing safe riding experience to its customers. It operates in one reportable segment which is vehicle manufacturing. SVH's first product line, the Prana, is a E2W vehicle that is redefining the category. SVH has commenced engineering and design work for the Prana-Elite that is expected to leverage the same platform as the Prana-Grand, while upgrading its range.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.